Resilience-Building Intervention for Older Informal Caregivers
14 de julho de 2026 atualizado por: Vivien Xi WU, PhD, National University of Singapore
Community-Based Resilience-Building Intervention for Older Informal Caregivers: Protocol for a Cluster Randomized Feasibility Trial
The goal of this pilot study is to test whether a newly developed resilience-building program is feasible and acceptable for older adults who provide unpaid care to people with functional impairment in the community. The program was developed based on earlier research with older caregivers, existing scientific evidence, and feedback from key stakeholders.
The main questions this study aims to answer are:
- Can older caregivers be successfully recruited and retained in the study?
- Is the program feasible and acceptable to deliver in community settings?
- Does the program show potential to improve resilience among older caregivers?
Researchers will compare:
- an intervention group receiving an 8-week multicomponent resilience-building intervention delivered through alternating in-person and online sessions at participating Active Ageing Centres and through Telegram group video calls. The program includes psychoeducation, peer support group, and access to an artificial intelligence (AI) chatbot developed to support caregivers.
- an active control group receiving access to the AI chatbot and weekly telephone follow-up only.
- a control group continuing their usual caregiving routine.
Participants will:
- Be assigned to 1 of the 3 study groups based on the Active Ageing Centre they attend.
- Complete self-reported questionnaires before the intervention (T0, baseline), immediately after the intervention (T1, post-intervention), and 3 months later (T2, follow-up).
- Some participants may also be invited to participate in focus group discussions after the 8-week intervention period as part of a process evaluation to explore their experiences, perceived usefulness of the intervention components, barriers and facilitators to participation, and recommendations for refinement.
Findings from this pilot study will help refine the intervention and study procedures of a larger future trial.
Visão geral do estudo
Status
Ainda não está recrutando
Tipo de estudo
Intervencional
Inscrição (Estimado)
90
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Ruochen Feng
- Número de telefone: +6566012756
- E-mail: rfeng@nus.edu.sg
Estude backup de contato
- Nome: Vivien Xi Wu
- E-mail: vivien.wu@nus.edu.sg
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- Be aged 60 to 85 years;
- Reside in the community;
- Be attending a participating Lions Befrienders Active Ageing Centre;
- Be able to communicate in English or Mandarin;
- Have an Abbreviated Mental Test (AMT) score of 8 or above;
- Self-identify as an informal caregiver providing unpaid care to a family member, friend, or other individual;
- Provide care to a care recipient with impairment in at least one activity of daily living, as assessed using the Older Americans Resources and Services Activities of Daily Living (OARS-ADL) scale;
- Have at least weekly contact with the care recipient.
Exclusion Criteria:
- Have severe visual or hearing impairment that would prevent participation in study activities;
- Have a known diagnosis of dementia or other severe cognitive impairment;
- Have a known diagnosis of a severe psychiatric disorder that may impair study participation (e.g., psychotic disorders);
- Have an AMT score below 8;
- Provide care primarily to grandchildren or children under 18 years of age, rather than to an adult with functional impairment.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Multicomponent Resilience-building Program
8-week multicomponent resilience-building intervention comprising alternating weekly in-person and online sessions.
Key components include: 1) psychoeducation; 2) peer support group sharing; and 3) access to an AI chatbot for caregiving support.
|
Participants in the intervention group will receive the THRIVE program, an 8-week multicomponent resilience-building intervention developed based on prior participant need assessment, empirical evidence on resilience theory and caregiver resilience interventions, and stakeholder input.
The intervention aims to strengthen psychological resilience among older informal caregivers.
The format will be alternating in-person and online sessions conducted weekly over 8 weeks.
In-person sessions will be held at participating Active Ageing Centres, while online sessions will be conducted through Telegram group video calls.
Each 1.5-hour session will include: 1) psychoeducation; 2) peer support group sharing; and 3) an AI chatbot trained using local official resources.
Sessions will be delivered by the same trained facilitator using a standardized intervention protocol.
An independent observer will complete a fidelity checklist during each session to assess adherence to the protocol.
|
|
Comparador Ativo: AI Chatbot and Telephone Follow-up Group
Access to the AI chatbot trained using local official health education and caregiving support resources, with weekly telephone follow-up calls to guide chatbot use and address technical difficulties.
|
Participants will receive access to the same AI chatbot trained using information from local official health education and caregiving support resources.
Participants will also receive weekly telephone follow-up calls from the research team over the 8-week study period.
The telephone follow-ups aim to: 1) encourage use of the AI chatbot; 2) address any technical difficulties encountered during chatbot use; and 3) gather participants' feedback and experiences using a standardized telephone follow-up guide.
All telephone calls will be audio-recorded and reviewed by the research team for fidelity monitoring to ensure consistency of delivery across participants.
|
|
Sem intervenção: Usual Practice
Participants in the control arm will not receive the intervention or access to the AI chatbot during the study period until the last follow-up assessment.
They will continue their usual caregiving routine and existing care practices as usual.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recruitment Rate
Prazo: From date of randomization until the date of first session of the intervention, assessed up to 2 months.
|
Proportion of eligible participants who provide informed consent and complete baseline assessment.
|
From date of randomization until the date of first session of the intervention, assessed up to 2 months.
|
|
Participant Retention Rate
Prazo: Assessed from the first session of the intervention to Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Proportion of enrolled participants who complete the post-intervention (T1) and 3-month follow-up (T2) assessments.
|
Assessed from the first session of the intervention to Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Intervention Adherence
Prazo: Throughout the 8-week intervention period.
|
Participant adherence to intervention activities, including attendance at in-person and online sessions, completion of telephone follow-up calls, and engagement metrics with the AI chatbot.
|
Throughout the 8-week intervention period.
|
|
Intervention Acceptability
Prazo: Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
Participant acceptability of the intervention will be assessed using a post-intervention satisfaction survey and qualitative feedback collected through focus group discussions to explore participants' experiences, perceived usefulness of the intervention, barriers and facilitators to participation, and recommendations
|
Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
|
AI Chatbot Usability
Prazo: Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
Usability of the AI chatbot will be assessed using the Simplified System Usability Scale (SUS).
The SUS consists of 10 items rated on a 5-point Likert scale.
Responses are converted to produce a total score ranging from 0 to 100, with higher scores indicating better perceived usability.
|
Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Psychological Resilience
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Assessed using the Connor-Davidson Resilience Scale (CD-RISC-25) to explore preliminary trends in intervention effects on resilience.
The CD-RISC-25 consists of 25 items, with total scores ranging from 0 to 100.
Higher scores indicate greater psychological resilience.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Intrinsic Capacity
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Intrinsic capacity will be assessed using the World Health Organization (WHO) Integrated Care for Older People (ICOPE) screening tool to explore preliminary trends in intervention effects on intrinsic capacity.
The tool assesses six domains of intrinsic capacity.
Each domain is scored as 1 if no impairment is identified and 0 if impairment is present, yielding a total score ranging from 0 to 6, with higher scores indicating better intrinsic capacity.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Health Self-Efficacy
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Health self-efficacy will be assessed using the Self-Rated Abilities for Health Practices Scale (SRAHP).
The SRAHP consists of 28 items assessing self-perceived ability to perform health-promoting behaviours across four domains: exercise, nutrition, responsible health practices, and psychological well-being.
Total scores range from 0 to 112, with higher scores indicating greater health self-efficacy for health-promoting practices.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Social Isolation
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Social isolation will be assessed using the Social Isolation Scale (SIS).
The SIS consists of 6 items assessing the size and quality of participants' social relationships and social connectedness.
Total scores range from 6 to 30, with higher scores indicating lower levels of social isolation (greater social connectedness) and lower scores indicating greater social isolation.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Caregiver burden
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Caregiver burden will be assessed using the 4-item Zarit Burden Interview (ZBI-4).
The ZBI-4 consists of 4 items assessing the perceived impact of caregiving on the caregiver's time, stress, strain, and uncertainty.
Total scores range from 0 to 16, with higher scores indicating greater caregiver burden.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
|
Resource Awareness and Navigation
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
This outcome will be assessed using a study-specific 2-item questionnaire developed for this pilot study.
The questionnaire evaluates participants' awareness of caregiving support services and confidence in accessing caregiving support when needed.
Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree).
Total scores range from 2 to 10, with higher scores indicating greater awareness and confidence in accessing caregiving support resources.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Exploratory digital engagement outcomes
Prazo: Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
Assessed using AI chatbot usage analytics, including interaction time, frequency, query categories and click-through rates for recommended resources.
|
Assessed at Post-intervention (T1): within 2 weeks after completion of the 8-week intervention.
|
|
Intracluster Correlation Coefficient for Future Trial Planning
Prazo: Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Estimated for key feasibility and exploratory outcome measures to inform sample size calculation and design considerations for a future definitive cluster randomized controlled trial.
|
Assessed across 3 time-points: Baseline (T0): within 2 weeks before the first intervention session. Post-intervention (T1): within 2 weeks after completion of the 8-week intervention. Follow-up (T2): within 2 weeks after the 3-month follow-up time point.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de agosto de 2026
Conclusão Primária (Estimado)
31 de março de 2027
Conclusão do estudo (Estimado)
31 de março de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
30 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
14 de julho de 2026
Primeira postagem (Real)
17 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
17 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
14 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- NUS-IRB-2023-889
- A-8001599-00-00 (Número de outro subsídio/financiamento: National University Health System Seed Grant)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Descrição do plano IPD
The decision regarding sharing of de-identified individual participant data has not yet been finalized.
Data sharing will be considered following study completion, taking into account participant consent, ethical and regulatory requirements, institutional policies, and the potential risk of participant re-identification due to the relatively small sample size and specific study population.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .